PRPO

Precipio Inc. (PRPO) | Rumor.io

Precipio

PRPO

Attention (50-day avg)0%

Attention rank (50-day avg)#3,099

Bullish sentiment (50-day avg)100%

Price to earnings ratio-105.1

Market capitalization43.2M

Earnings per share-0.62

Dividend yield (TTM)—

Revenue (annual)24M

Net income (annual)-363K

Social

What share of all stock conversation is about PRPO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 19

The stock $PRPO is setting up nicely for a potential price increase, with some investors expecting a significant rise to 3-4 digit numbers.
A big investor is reportedly in talks with Precipio, Inc. to potentially invest in the company, which could lead to a substantial increase in the stock price.
The stock price of $PRPO has been volatile, with some users expecting a parabolic run and others predicting a significant increase to 60+ dollars.

Generated by AI

Sentiment

Of the messages about PRPO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	96.94% +7.47
Bearish	—	—	0% 0	3.06% -7.47

Bullish· Sep 8

$PRPO has the potential to reach $50 per share, making it an opportunity of a lifetime for investors.
A big pharma buyout is a prime possibility for Precipio, Inc., which could significantly increase the company's value.
Breaking above the $20.00 price level could trigger buy orders, pushing the stock price even higher.

Bearish· Sep 22

The company's stock price has declined significantly, with some investors averaging losses of over $100 per share.
The company's management, particularly Ilan, has been criticized for their handling of the company's finances and lack of transparency.
The company's low float (1 million shares) and history of reverse splits may make it vulnerable to further price declines and potential dilution of shareholder value.

Generated by AI

Topics

Of the messages about PRPO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	33.33%	70.31%
Technical Analysis	—	—	33.33%	13.02%
Controversies	—	—	33.33%	0.52%
Earnings	—	—	0%	16.15%
Analysts	—	—	0%	0%
Macro	—	—	0%	0%

Earnings· Aug 20

* Expectations for Precipio, Inc.'s earnings call include revenues and profits, as well as potential new deals.

Announcements· Sep 15

Precipio, Inc. (PRPO) has signed an agreement with another major US healthcare distributor for its HemeScreen product, potentially adding $100M to the market.
The agreement's terms are not disclosed, and shares of PRPO were halted on a circuit breaker.
Trading for PRPO has resumed after being halted, with the stock experiencing a 10.08% decline to $1.07 in the last 15 minutes.

Technical Analysis· Jun 8

The 5/3 support level and key price levels at 4.50 and 4.90 are being watched, with a potential breakout above 4.90 leading to a parabolic move to 5.30+.
The stock is holding above the 200 SMA and has not yet reached the Top Keltner (4.65) or Top Bollinger (4.55) levels, with a potential move higher if it breaks above 4.90.
A bull flag is forming, with a potential breakout above 4.30 leading to further uptrend, and a semi-parabolic move to 5.46 if the stock breaks above 5.24.

Generated by AI

Community

Of the messages about PRPO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	75%	69.53%
Newcomers	—	—	25%	30.47%

Regulars· May 10

Precipio Signs First IV-Cell Customer Agreement, a significant development that may lead to a surge in the company's stock price.
The MACD Histogram for $PRPO has turned negative, indicating a potential decline in the stock's value.
$PRPO's price has broken below the lower Bollinger Band, suggesting a possible increase in the stock's value.

Newcomers· Sep 15

Precipio, Inc. (PRPO) has signed an agreement with another major US healthcare distributor for its HemeScreen product, which could represent an additional $100M in market potential.
The agreement has caused PRPO's stock to be halted on the NASDAQ due to price volatility, with the stock experiencing a significant price increase and trading resumed after the halt was lifted.
PRPO's stock has experienced a significant price increase, with the stock up 16.11% and trading at $1.11, and has been identified as a potential trading opportunity due to its relatively large volume.

Generated by AI

News

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Detailed price information for Precipio Inc (PRPO-Q) from The Globe and Mail including charting and trades.

7d agoThe Globe and Mail

Precipio Q2 2026 Earnings Call: Complete Transcript

12d agoBenzinga

The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio

Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks.

19d agoYahoo Finance

Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong

PRPO's second-quarter 2026 revenue momentum strengthens on higher diagnostic volumes and record product sales, alongside positive adjusted EBITDA and cash generation.

1mo agoYahoo Finance

Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ...

1mo agoYahoo Finance

Earnings call transcript: Precipio tops $7 million in Q2 2025 as growth turns profitable

1mo agoInvesting.com

Also Discussed

Investors talking about PRPO also mention

#	Name	Attention
1	Immunic, Inc.IMUX	0%0
2	OBLN - Obalon Therapeutics, Inc.	——
3	RHE - Regional Health Properties, Inc.	——
4	Moleculin Biotech, Inc.MBRX	0%0
5	AVGR - Avinger, Inc.	——
6	Legacy Education Inc.LGCY	0%new
7	ABIO - ARCA biopharma, Inc.	——
8	SEEL - Seelos Therapeutics, Inc.	——
9	Bio-Path Holdings Inc.BPTH	0%0
10	Bridgeline Digital IncBLIN	0%new

Precipio Inc.

Healthcare
Diagnostics & Research

Precipio Inc. is a healthcare biotechnology company focused on cancer diagnostics, with a particular emphasis on hematologic malignancies and laboratory error reduction. The company provides specialized diagnostic services for blood cancers and develops proprietary products used by pathology laboratories, including genetic panels, cell culture media, and related assay technologies. Its business is organized around diagnostic services and diagnostic products, creating an integrated platform that supports testing, workflow efficiency, and clinical decision-making. Precipio Inc. also serves biopharma customers through biomarker testing and clinical project services. Based in New Haven, Connecticut, the company operates in the clinical diagnostics and life sciences markets, where it aims to improve the accuracy and utility of cancer testing for physicians, laboratories, and patients.

Website

Location

4 Science Park

New Haven, CT, 06511

United States

Social

What share of all stock conversation is about PRPO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Nov 19

The stock $PRPO is setting up nicely for a potential price increase, with some investors expecting a significant rise to 3-4 digit numbers.
A big investor is reportedly in talks with Precipio, Inc. to potentially invest in the company, which could lead to a substantial increase in the stock price.
The stock price of $PRPO has been volatile, with some users expecting a parabolic run and others predicting a significant increase to 60+ dollars.

Generated by AI

Sentiment

Of the messages about PRPO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	96.94% +7.47
Bearish	—	—	0% 0	3.06% -7.47

Bullish· Sep 8

$PRPO has the potential to reach $50 per share, making it an opportunity of a lifetime for investors.
A big pharma buyout is a prime possibility for Precipio, Inc., which could significantly increase the company's value.
Breaking above the $20.00 price level could trigger buy orders, pushing the stock price even higher.

Bearish· Sep 22

The company's stock price has declined significantly, with some investors averaging losses of over $100 per share.
The company's management, particularly Ilan, has been criticized for their handling of the company's finances and lack of transparency.
The company's low float (1 million shares) and history of reverse splits may make it vulnerable to further price declines and potential dilution of shareholder value.

Generated by AI

Topics

Of the messages about PRPO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	33.33%	70.31%
Technical Analysis	—	—	33.33%	13.02%
Controversies	—	—	33.33%	0.52%
Earnings	—	—	0%	16.15%
Analysts	—	—	0%	0%
Macro	—	—	0%	0%

Earnings· Aug 20

* Expectations for Precipio, Inc.'s earnings call include revenues and profits, as well as potential new deals.

Announcements· Sep 15

Precipio, Inc. (PRPO) has signed an agreement with another major US healthcare distributor for its HemeScreen product, potentially adding $100M to the market.
The agreement's terms are not disclosed, and shares of PRPO were halted on a circuit breaker.
Trading for PRPO has resumed after being halted, with the stock experiencing a 10.08% decline to $1.07 in the last 15 minutes.

Technical Analysis· Jun 8

The 5/3 support level and key price levels at 4.50 and 4.90 are being watched, with a potential breakout above 4.90 leading to a parabolic move to 5.30+.
The stock is holding above the 200 SMA and has not yet reached the Top Keltner (4.65) or Top Bollinger (4.55) levels, with a potential move higher if it breaks above 4.90.
A bull flag is forming, with a potential breakout above 4.30 leading to further uptrend, and a semi-parabolic move to 5.46 if the stock breaks above 5.24.

Generated by AI

Community

Of the messages about PRPO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	75%	69.53%
Newcomers	—	—	25%	30.47%

Regulars· May 10

Precipio Signs First IV-Cell Customer Agreement, a significant development that may lead to a surge in the company's stock price.
The MACD Histogram for $PRPO has turned negative, indicating a potential decline in the stock's value.
$PRPO's price has broken below the lower Bollinger Band, suggesting a possible increase in the stock's value.

Newcomers· Sep 15

Precipio, Inc. (PRPO) has signed an agreement with another major US healthcare distributor for its HemeScreen product, which could represent an additional $100M in market potential.
The agreement has caused PRPO's stock to be halted on the NASDAQ due to price volatility, with the stock experiencing a significant price increase and trading resumed after the halt was lifted.
PRPO's stock has experienced a significant price increase, with the stock up 16.11% and trading at $1.11, and has been identified as a potential trading opportunity due to its relatively large volume.

Generated by AI

Precipio

Social

Nov 19

Bullish· Sep 8

Bearish· Sep 22

Earnings· Aug 20

Announcements· Sep 15

Technical Analysis· Jun 8

Regulars· May 10

Newcomers· Sep 15

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Precipio Q2 2026 Earnings Call: Complete Transcript

The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio

Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong

Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ...

Earnings call transcript: Precipio tops $7 million in Q2 2025 as growth turns profitable

Also Discussed

Precipio Inc.

Company Information

Location

PRPO vs. FLGT: Which Cancer Diagnostics Stock Has More Upside Now?

Precipio Q2 2026 Earnings Call: Complete Transcript

The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio

Precipio Stock Gains Post Q2 Earnings, Revenue Momentum Strong

Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ...

Earnings call transcript: Precipio tops $7 million in Q2 2025 as growth turns profitable

Also Discussed

Social

Nov 19

Bullish· Sep 8

Bearish· Sep 22

Earnings· Aug 20

Announcements· Sep 15

Technical Analysis· Jun 8

Regulars· May 10

Newcomers· Sep 15